Humanitas University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Pieve Emanuele Italy (2014)

Organization Overview

First Clinical Trial
2014
NCT00410696
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Armando Santoro, MD | Cliniche Humanitas Gavazzeni | Fondazione Humanitas per la Ricerca | Humanitas Cancer Center - Department of Medical Oncology and Haematology | Humanitas Cancer Centre, IRCCS Humanitas Research Hospital | Humanitas Clinical and Research Center | Humanitas Clinical and Research Centre | Humanitas Clinical and Research Hospital | Humanitas Gavazzeni - Bergamo, Lombardia | Humanitas Hospital, Italy | HUMANITAS RESEARCH HOSPITAL | Humanitas Research Hospital Milan | Humanitas Research Hospital, Rozzano | Humanitas University | IBD Center, Humanitas Research Hospital, Rozzano (MI) ITALY | IBD Center, Instituto Clinico Humanitas, Department of Gastroenterology, Via Manzoni 56, 20089 Rozzano, Milan, Italy | Instituto Clinico Humanitas, Milano | IRCCS Humanitas Research Hospital | IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy

Active Ingredients

Drugs in Phase 4 Trials (4)

acetylsalicylic acid (aspirin) (1 trial)

golimumab (simponi) (1 trial)

metformin (glucophage) (1 trial)

palmitoylethanolamide (1 trial)

Drugs in Phase 3 Trials (13)

benralizumab (fasenra) (1 trial)

cannabidiol (Epidiolex) (1 trial)

carboplatin (paraplatin) (4 trials)

cyclophosphamide (cytoxan) (1 trial)

gefitinib (iressa) (1 trial)

hyaluronic acid (1 trial)

lenalidomide (revlimid) (1 trial)

letrozole (femara) (1 trial)

methylprednisolone (medrol) (1 trial)

nebivolol (bystolic) (1 trial)

ozone (1 trial)

paclitaxel (taxol) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 2 Trials (21)

bendamustine (treanda) (1 trial)

bevacizumab (avastin) (1 trial)

bleomycin (blenoxane) (1 trial)

cisplatin (platinol) (1 trial)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (1 trial)

everolimus (zortress) (1 trial)

Filgrastim (neupogen) (1 trial)

gemcitabine (gemzar) (3 trials)

pemetrexed (alimta) (3 trials)

pioglitazone (actos) (1 trial)

sargramostim (leukine) (1 trial)

tivantinib (2 trials)

topotecan (hycamtin) (1 trial)

trabectedin (yondelis) (1 trial)

tralokinumab (Adtralza) (1 trial)

trastuzumab (herceptin) (1 trial)

triptorelin (Trelstar) (1 trial)

vinblastine (velban) (1 trial)

vinorelbine (navelbine) (2 trials)

vorinostat (zolinza) (1 trial)

Drugs in Phase 1 Trials (4)

ifosfamide (ifex) (1 trial)

panobinostat (farydak) (1 trial)

prednisone (meticorten) (1 trial)

rp6530 (1 trial)

Drugs in Other Trials (4)

acetic acid (vosol) (1 trial)

ephedrine (1 trial)

etilefrine (1 trial)

norepinephrine (levophed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Hematologic Neoplasms (Phase 2)

Hodgkin Disease (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Mantle-Cell (Phase 3)

Mesothelioma (Phase 2)

Nasal Polyps (Phase 3)

Neoplasms (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Polyps (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Thymoma (Phase 2)

Thymus Neoplasms (Phase 2)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 46